Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 22.51B, Biogen(BIIB) trades at $153.43. The stock has a price-to-earnings ratio of 13.62.
As of 2025-11-06, Biogen(BIIB) stock has fluctuated between $148.90 and $153.66. The current price stands at $153.43, placing the stock +3.0% above today's low and -0.1% off the high.
The Biogen(BIIB)'s current trading volume is 1.74M, compared to an average daily volume of 1.89M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $179.20 and a 52-week low of $110.04.
In the last year, Biogen(BIIB) shares hit a 52-week high of $179.20 and a 52-week low of $110.04.
BIIB News
BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating today. Elevate Your Investing Strategy: Take advantage of Ti...
Biogen (BIIB) will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology’s annual meeting,...
Bernstein raised the firm’s price target on Biogen (BIIB) to $157 from $155 and keeps a Market Perform rating on the shares following quarterly results. The per...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Biogen Inc. recently reported third-quarter 2025 earnings, delivering revenue of US$2.53 billion and net income of US$466.5 million, both ahead of consensus est...
Biogen Inc. ((BIIB)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Pre...
Biogen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the sto...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen, with a price target of $150.00. Elevate Your Investing Strat...
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Biogen. The associated price target remains the same with $149.00. Elevate Your Inv...
Biogen Inc. ( (BIIB) ) has released its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Elevate Your Investing Strat...
Biogen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Phil Nadeau from TD Cowen maintained a Buy rating on the stock and...